EcoDrugPlus

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSLCAG00010019037
Gene Symbol: HTR1B
2 Cross references
182 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSLCAG00010021370
Gene Symbol: HTR1B
2 Cross references
181 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSLCAG00010002187
Gene Symbol: HTR1E
2 Cross references
146 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSLCAG00010001867
Gene Symbol: HTR2A
4 Cross references
213 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSLCAG00010014653
Gene Symbol: HTR3A
1 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSLCAG00010004387
Gene Symbol: HTR4
1 Cross references
198 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSLCAG00010002277
Gene Symbol: HTR5A
2 Cross references
208 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSLCAG00010023338
Gene Symbol: HTR5A
4 Cross references
208 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSLCAG00010005863
Gene Symbol: HTR6
4 Cross references
114 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSLCAG00010002160
Gene Symbol: HTR7
4 Cross references
196 Possible Orthologues:

60s Ribosomal Protein L10

Ensembl ID : ENSLCAG00010012546
Gene Symbol: LOC108887522
4 Cross references
396 Possible Orthologues:

60s Ribosomal Protein L10

Ensembl ID : ENSLCAG00010004182
Gene Symbol: LOC108887522
4 Cross references
396 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).